Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy
- PMID: 11273061
- DOI: 10.1016/S0140-6736(00)04005-8
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy
Abstract
Background: A previous study suggested that severe left-ventricular hypertrophy (maximum wall thickness > or = 30 mm) in patients with hypertrophic cardiomyopathy is associated with a risk of sudden cardiac death sufficient to warrant consideration for implantation of a cardioverter defibrillator (ICD). However, the prognostic significance of left-ventricular hypertrophy in relation to other clinical risk factors is poorly characterised.
Methods: We studied 630 patients consecutively referred to one hospital in London, UK (mean age 37 years [SD 16]; 382 male; mean follow-up 59 months). Patients underwent two-dimensional and doppler echocardiography, upright exercise testing, and Holter monitoring.
Findings: 39 patients died suddenly or had an appropriate ICD discharge; nine died from progressive heart failure; 11 from other cardiovascular causes and 23 from non-cardiac causes. There was a trend towards higher probability of sudden death or ICD discharge with increasing wall thickness (p=0.029, relative risk per 5 mm increment 1.31 [95% CI 1.03-1.66]). Of the 39 patients who died suddenly or had an ICD discharge, ten had a wall thickness of 30 mm or more. Patients with wall thickness of 30 mm or more had higher probability of sudden death or ICD discharge than patients with wall thickness less than 30 mm (p=0.049, 2.07 [1.00-4.25]. When considered together, the number of additional risk factors (one to three) was a better predictor of risk of sudden death or ICD discharge than wall thickness (p=0.0001, relative risk per additional factor 2.00 [1.43-2.79] vs p=0.058, 1.26 per 5 mm increment [0.99-1.60]). There was no relation between the pattern of hypertrophy and survival.
Interpretation: The risk of sudden death associated with a wall thickness of 30 mm or more in patients without other risk factors is insufficient to justify aggressive prophylactic therapy. Most sudden deaths occurred in patients with wall thickness less than 30 mm, so the presence of mild hypertrophy cannot be used to reassure patients that they are at low risk.
Comment in
-
Risk management in hypertrophic cardiomyopathy.Lancet. 2001 Feb 10;357(9254):407-8. doi: 10.1016/S0140-6736(00)04022-8. Lancet. 2001. PMID: 11273054 No abstract available.
-
Sudden death and hypertrophic cardiomyopathy.Lancet. 2001 Jun 16;357(9272):1975-6. doi: 10.1016/S0140-6736(00)05039-X. Lancet. 2001. PMID: 11430387 No abstract available.
Similar articles
-
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.JAMA. 2007 Jul 25;298(4):405-12. doi: 10.1001/jama.298.4.405. JAMA. 2007. PMID: 17652294
-
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35. doi: 10.1016/j.jacc.2013.01.037. J Am Coll Cardiol. 2013. PMID: 23500286
-
Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.Eur Heart J. 2009 Nov;30(21):2599-605. doi: 10.1093/eurheartj/ehp327. Epub 2009 Aug 17. Eur Heart J. 2009. PMID: 19689975
-
Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.J Cardiovasc Electrophysiol. 2008 Oct;19(10):1118-26. doi: 10.1111/j.1540-8167.2008.01147.x. Epub 2008 Mar 31. J Cardiovasc Electrophysiol. 2008. PMID: 18384577 Review.
-
Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.Anadolu Kardiyol Derg. 2006 Dec;6 Suppl 2:55-60. Anadolu Kardiyol Derg. 2006. PMID: 17162272 Review.
Cited by
-
Assessment of left ventricular wall thickness and dimension: accuracy of a deep learning model with prediction uncertainty.Int J Cardiovasc Imaging. 2024 Oct;40(10):2157-2165. doi: 10.1007/s10554-024-03207-7. Epub 2024 Aug 10. Int J Cardiovasc Imaging. 2024. PMID: 39126604
-
Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy.Cardiovasc Diagn Ther. 2019 Oct;9(Suppl 2):S299-S309. doi: 10.21037/cdt.2019.05.01. Cardiovasc Diagn Ther. 2019. PMID: 31737538 Free PMC article.
-
Pregnancy related complications in women with hypertrophic cardiomyopathy.Heart. 2003 Jul;89(7):752-6. doi: 10.1136/heart.89.7.752. Heart. 2003. PMID: 12807849 Free PMC article.
-
ST segment "hump" during exercise testing and the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy.Ann Noninvasive Electrocardiol. 2009 Apr;14(2):158-64. doi: 10.1111/j.1542-474X.2009.00291.x. Ann Noninvasive Electrocardiol. 2009. PMID: 19419401 Free PMC article.
-
Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines.Heart Fail Rev. 2025 Mar;30(2):315-325. doi: 10.1007/s10741-024-10464-0. Epub 2024 Nov 9. Heart Fail Rev. 2025. PMID: 39520615 Review.
MeSH terms
LinkOut - more resources
Full Text Sources